Marimed (MRMD) Cash from Financing Activities (2014 - 2026)

Marimed (MRMD) has 13 years of Cash from Financing Activities data on file, last reported at -$1.1 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 9.21% year-over-year to -$1.1 million in Q1 2026; TTM through Mar 2026 was -$4.6 million, a 5775.31% decrease from a year earlier, with the FY2025 full-year figure at -$4.7 million, down 257.89% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$1.1 million, down from -$944000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for MRMD reached as high as $23.3 million in Q1 2023 and fell as low as -$3.1 million in Q3 2023.
• Historically, Cash from Financing Activities has averaged $1.1 million across 5 years, with a median of -$806000.0 in 2025.
• Across the five-year window, Cash from Financing Activities slumped 1349.15% in 2022 and surged 7176.6% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at -$600000.0 in 2022, then soared by 850.0% to $4.5 million in 2023, then slumped by 119.84% to -$893000.0 in 2024, then decreased by 5.71% to -$944000.0 in 2025, then declined by 21.08% to -$1.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$1.1 million in Q1 2026, -$944000.0 in Q4 2025, and -$1.7 million in Q3 2025.